From the rapid pace of pathogenesis to questions about vaccine boosters
Photo credit: Debenport/E+/Getty Images
The Advisory Committee on Immunization Practices (ACIP) develops written recommendations for the routine administration of vaccines, in addition to schedules regarding the appropriate timing, dosage, and contraindications. Key factors – the balance between benefits and harm, the evidence type or quality, values and preferences, and health economic analyses – are used to refine the recommendation and to determine what category of recommendation is made, either Category A or Category B. Read more to discover why ACIP decided on a Category B recommendation for the MenB vaccines.read more
Parents sometimes are hesitant to allow their children to receive vaccines. Read about why parents may be hesitant or refuse to allow their teens to receive the MenB vaccines during an outbreak of Neisseria meningitides serotype B infections and how to talk with these parents.read more
The Food and Drug Administration granted Pfizer’s serogroup B bivalent meningococcal vaccine, brand name Trumemba, breakthrough therapy status, approving it as the first MenB vaccine for use in 1- to 9-year-olds. Read more about why it did so.read more
There are two currently FDA-licensed MenB vaccines available in the United States. There are specific indications for the vaccine based on Category A (high-risk patients and situations) and Category B (healthy adolescents) as outlined by the Advisory Committee on Immunization Practices.
It is important to familiarize yourself with the vaccine that is used in your practice. Your personal and professional experience with the vaccine as the provider is important to be able to share with your patients, including the side effects associated with that particular vaccine.
Coadministration of multicomponent meningococcal serogroup B vaccine with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type B (DTPa-HBV-IPV/Hib) vaccine demonstrated acceptable immunogenicityread more
A booster shot of the investigational combined meningococcal vaccine MenABCWY provided robust antibody response against five serogroups of meningococcal disease, according to results of a phase 2, randomized, controlled trial.read more
The pace of pathogenesis for Neisseria meningitidis infection is very rapid. In a matter of hours bacteria can attach to epithelial cells of the nasopharynx and then gain entry to the blood and lymphatics. From there the bacteria seed multiple sites such as skin and vital organs. The result is meningococcemia and, in some cases, meningococcal meningitis. The consequences are dire, with loss of limb and life.read more